Disclosed is a biochemical-immunological hybrid biosensor. The biochemical-immunological hybrid biosensor includes a reaction strip in the form of a porous membrane through which a sample moves by capillary action. The reaction strip can simultaneously measure heterogeneous multiple biomarkers through both a biochemical analysis and an immunoassay in an independent manner based on membrane chromatography to diagnose a particular disease.

A method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response and suspected of having an infection. Also, a method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response, wherein the comorbidity is preferably selected from the group comprising metabolic disorder (obesity), diabetes, hypertension, renal disease, thrombosis, malignancy or cancer, and suspected of having an infection. In particular, the method comprises providing a sample from said patient and determining a level of PCT or fragment(s) thereof in said sample, wherein the level of PCT or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. Furthermore, a kit for carrying out the method of the present invention.

The present invention provides for a new therapeutic tools capable of treating infectious diseases, in particular, a new pharmaceutical composition comprising an IgM-enriched immunoglobulin preparation for use in the adjunctive treatment of severe Community Acquired Pneumonia (sCAP).

A method of determining a management course for treating a subject showing symptoms of a disease is disclosed. The method comprises measuring the TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is above a predetermined amount, the subject is treated as a low-risk patient.

A normal incident guided-mode-resonance biosensor and procalcitonin detection method using the same are provided and include a light source, a first lens, a polarizer, a beam splitter, a wave plate, a second lens, a detection unit, and a processing unit. The light source provides a light beam. The first lens converts the light beam into a parallel light. The polarizer filters and removes a transverse electric field mode light wave in the parallel light. The beam splitter selectively forms a transverse magnetic field mode light wave in the parallel light. The wave plate rotates the transverse magnetic field mode light wave in the parallel light by 45. The second lens focuses the transverse magnetic field mode light wave to the bio-sensing chip. The detection unit receives an emitted light of the bio-sensing chip and generates a sensing signal.

This disclosure describes portable bio-nano-chip assays, methods and compositions for diagnosing trauma at point-of-care using biological samples. The assays, methods and compositions provide in a more convenient, less expensive, and less time-consuming sampling and analysis.

Subject of the present invention are assays and in vitro methods for the in vitro diagnosis, prognosis and risk stratification of a patient having a primary, non-infectious disease, whereby the level of Procalcitonin (PCT) in a sample of a body fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition.

Disclosed is a localised surface plasmon resonance (LSPR) nanopillar assembly. The LSPR assembly is for use in sensing the presence of a biomarker when attached to a quantum dot. The LSPR assembly comprises a substrate and an array. The array comprises a LSPR nanopillar and a polymer spacer attached to the nanopillar. The LSPR assembly further comprises an antibody attached to the at least one polymer spacer. In the LSPR assembly, a combined height of the polymer spacer and antibody is selected by varying the number of monomer units of the polymer spacer, so that, when in use with the biomarker and the quantum dot, the quantum dot is at a predetermined distance from the nanopillar.

The present invention relates to methods for detecting cell death in a cell or a sample comprising cells, or in cultured cells in vitro by detecting the level of calcitonin receptor. The present invention also relates to methods of imaging cell death in a subject, compositions useful for detecting cell death in a cell or in a subject, methods of screening for modulators of cell death, and methods of staging and monitoring the progress of disease by detecting cell death.

Subject of the present invention are assays and in vitro methods for the in vitro diagnosis, prognosis and risk stratification of a patient having a primary, non-infectious disease, whereby the level of Procalcitonin (PCT) in a sample of a body fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition.